LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the drug pipeline for the atypical hemolytic uremic syndrome. The report includes a detailed analysis of the ...
Please provide your email address to receive an email when new articles are posted on . The FDA today granted fast track status to OMS721 — a complement inhibitor — for the treatment of patients with ...
- At 26 weeks, 54% of adults and 71% of children treated with ULTOMIRIS demonstrated Complete Thrombotic Microangiopathy (TMA) Response - Atypical HUS affects both adults and children and many ...
Please provide your email address to receive an email when new articles are posted on . Atypical hemolytic uremic syndrome is a rare condition caused by the uncontrolled activation of complement, and ...
The US Food and Drug Administration (FDA) has approved ravulizumab (Ultomiris, Alexion Pharmaceuticals) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adults and children age 1 ...
SEATTLE, Wash.--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that data from the dose-ranging stage of the Phase 2 clinical trial evaluating OMS721 in the treatment of atypical ...
Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H-related 5 gene
The research population consisted of 65 aHUS patients, referred to the Paediatric Nephrology Centre of the Radboud University Medical Centre. The patients were of Dutch or Belgian origin with a ...
Alexion announced that results from its Phase 2 study of Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy. The ...
The management of patients with hemolytic uremic syndrome is challenging, and strategies for accurate diagnosis and effective treatment are needed. Intensive research over the past several years has ...
June 7, 2012 (Paris, France) — Children with atypical hemolytic-uremic syndrome (aHUS) had a robust response to eculizumab (Soliris) in real-life clinical settings. The finding mirrors clinical trial ...
Atypical hemolytic–uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels ...
Hemolytic uremic syndrome (HUS) is a condition that affects the blood vessels in your kidneys. When the vessels are damaged, they form clots that block the kidney's regular filtering system, leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results